Douglas Tavares: Why Patient Blood Management Remains Underused Despite Decades of Evidence

Douglas Tavares, Adjunct Professor of Business at Florida Southern College, shared a post on LinkedIn:

“This week marks Patient Blood Management (PBM) Awareness Week across the globe.

It serves as a vital checkpoint for modern medicine—a dedicated moment to pause and critically evaluate how healthcare systems optimize patient blood, steward scarce clinical resources, and protect long-term institutional solvency.

Yet, true awareness requires more than nominal recognition; it demands an honest audit of clinical reality.

This analysis is directed to the clinical and operational leadership shaping the delivery of modern medicine: Chief Medical Officers, Chief Executive Officers, Chief Financial Officers, Nurse Leaders, Health Ministers, Public Health Policy Directors, Payers, and Healthcare Investors.

The objective is straightforward: to confront a systemic blind spot that sits at the exact intersection of clinical quality, bioethics, and financial viability.

To understand why Patient Blood Management is no longer an optional clinical interest but an institutional imperative, we must examine it across three critical macroeconomic and clinical realities:

The Fragility of Modern Healthcare Financial Sustainability: Operating margins are tightening under labor shortages, escalating supply expenses, and value-based penalty models.

Evolving Patient Safety and Clinical Expectations: Contemporary patients demand individualized, minimally invasive, and complications-minimized care pathways.

The Ongoing Blood Supply Crisis and Hidden Operational Drag: Blood is a scarce, costly, and biologically active liquid organ transplant whose administration carries systemic operational risk and substantial direct and indirect costs.

Deconstructing the Four Waves of Patient Blood Management

A persistent myth within certain leadership circles is that PBM is an experimental, fringe protocol or an academic exercise tailored exclusively for a narrow subset of specialized surgical patients.

This misconception ignores more than a quarter-century of established translational science and clinical trials.

In clinical medicine, therapeutic interventions typically advance through rigorous developmental phases before earning status as standard-of-care.

Patient Blood Management has methodically navigated all four:

• Wave 1: Clinical Discovery and Hypothesis Testing. Initial controlled cohorts revealed a provocative finding: patients managed through proactive blood optimization rather than routine allogeneic blood transfusion exhibited superior clinical outcomes.
• Wave 2: Multi-Center Trial Proliferation. Across cardiac, orthopedic, oncologic, and critical care specialties, large-scale clinical trials repeatedly established that minimizing blood loss, addressing preoperative anemia, and tolerating physiologic anemia reduced infection rates, end-organ complications, and length of stay (LOS).
• Wave 3: International System Integration. Over the past fifteen years, tertiary academic medical centers across the United States, Europe, and Australia demonstrated that hospital-wide PBM programs generated substantial clinical and financial dividends, sharply reducing unnecessary biological waste and operational expenditure.
• Wave 4: The Strategic Imperative (The Current Era). We have entered an era where PBM is recognized not merely as a transfusion-reduction effort, but as a cornerstone of high-reliability medicine, clinical governance, and institutional resilience.

Respected bodies across the global medical landscape—including the World Health Organization (WHO), the Society for the Advancement of Patient Blood Management (SABM), the Network for the Advancement of Patient Blood Management, Hemostasis and Thrombosis (NATA), the Association for the Advancement of Blood and Biotherapies (AABB), and the Red Cross—have formally endorsed PBM as an essential pillar of health system governance.

The Core Dilemma: Implementation versus Adoption

Last September, during the 25th SABM Annual Meeting, where I had the privilege of speaking, Prof. Dr. Aryeh Shander delivered an insight that captures the systemic impasse of modern hospital administration:

‘We do not have a PBM implementation problem; we have a PBM adoption problem.’

The distinction is profound.

Implementation relates to operational toolkits, laboratory protocols, electronic medical record (EMR) clinical decision support, and multidisciplinary algorithms.

The medical community has already built, tested, and validated these workflows.

There are no remaining scientific, logistical, or procedural barriers that prevent an institution from deploying PBM immediately.

Adoption, by contrast, is cultural, behavioral, and administrative.

It reflects the gap between available evidence and actual clinical practice.

Despite decades of PBM validated evidence and proven models across world-class institutions, adoption remains the weakest link in the healthcare ecosystem.

Why does this persistent lag endure?

My field experience and health-system observations reveal four key ecosystem failures:

1. The Executive Blind Spot Regarding Return on Investment (ROI): Hospital C-suites frequently overlook the massive economic leverage of PBM, often categorizing it erroneously as an operational expense rather than a high-yield clinical risk-mitigation strategy.
2. The Underutilization of Patient Empowerment: Patients routinely advocate for minimally invasive surgeries or innovative pharmacotherapies, yet they are rarely educated on the critical nature of their own blood health. Medical device and pharmaceutical leaders have a clear opportunity—and social responsibility—to educate patients on anemia management and blood health just as they do with other critical therapeutic innovations.
3. Absence of Cohesive National Public Health Policies: While some jurisdictions have pioneered national mandates, many health ministries have yet to integrate comprehensive PBM frameworks into standard licensing, accreditation, and quality-scoring regimes. ]
4. Payer Under-Engagement: Third-party payers and health insurance administrators continue to absorb the downstream financial fallout of avoidable hospital-acquired infections, prolonged stays, and readmissions, rather than actively incentivizing PBM adoption through value-based payment architectures.

Clinical Dividends and Macroeconomic Pressures

The data supporting PBM are symmetrical: the clinical gains directly address modern healthcare’s severe financial strain.

Documented Clinical Dividends of PBM:

Shortened Length of Stay (LOS): Optimized physiological reserves and reduced transfusion-related immunomodulation (TRIM) consistently correlate with faster recovering, reduced ICU stay, and accelerated discharge timelines.

Decreased Readmissions and Perioperative Complications: Multicenter data confirm statistically significant reductions in acute kidney injury, surgical-site infections, fluid overload, and pulmonary complications.

Oncologic Considerations: Growing literature links the mitigation of perioperative transfusion-related immunosuppression with reduced tumor recurrence rates in surgical oncology populations.

Operational Margin Protection and ROI: By curtailing unnecessary acquisition, testing, storage, and cross-matching costs—coupled with avoiding acute adverse-event management—PBM delivers substantial, rapid financial returns relative to its minimal upfront cost.

The Macroeconomic Reality

Modern healthcare cannot afford clinical waste.

The macroeconomic reality facing healthcare leadership today is characterized by relentless fiscal strain and unsustainable cost trajectories.

In the United States—a dynamic mirrored across many industrialized nations—healthcare spending has ballooned to absorb more than 18 percent of the Gross Domestic Product (GDP), demanding an overwhelming 5.3 trillion dollars annually.

To put this in global perspective, data from the Organization for Economic Cooperation and Development (OECD) show that average healthcare spending among developed nations hovers around 9 percent of GDP—meaning U.S. spending is roughly double that baseline.

While healthcare stands as the nation’s single largest employment sector, it faces critical, worsening workforce shortages that steadily drive labor expenses upward and compress hospital operating margins.

Compounding this systemic pressure, projections from the Centers for Medicare and Medicaid Services (CMS) indicate that national healthcare spending will continue its steep ascent, accelerating at an average annual rate of 5.4 percent through 2034.

A historical examination reveals the sheer velocity of this financial escalation.

In 1960, total U.S. healthcare spending stood at 27 billion dollars (or 5 percent of the U.S. GDP); by 2020, that figure surged to 4.1 trillion dollars, ultimately reaching 5.3 trillion dollars by 2024.

In an environment where systemic costs and clinical overhead outpace baseline economic growth, health systems can no longer absorb avoidable complications and clinical waste, making high-yield, resource-conserving strategies an operational imperative.

Against this economic backdrop, PBM represents an uncommon management instrument: a protocol requiring minimal capital expenditure that simultaneously elevates standard-of-care quality and systematically cuts high-cost clinical waste.

An Executive Challenge

Throughout decades of my immersion in healthcare management, clinical literature, and health economics, I have found few clinical interventions similar to Patient Blood Management.

It is rare to encounter a medical methodology that:

• Empirically improves patient survival, recovery, and long-term outcomes;
• Systematically removes unnecessary variable operating costs from surgical and medical services;
• Exceeds current baselines for clinical quality metrics; and
• Fully aligns with the highest international tenets of bioethics, patient autonomy, and medical law.

To delay the adoption of a framework endorsed by the World Health Organization and leading Medical Societies around the globe is no longer an administrative oversight—it is a governance failure.

The central question facing health systems today is therefore not:

‘Should our institution consider adopting Patient Blood Management?’

The definitive question every board member, chief medical officer, and healthcare minister must ask is:

‘Why is Patient Blood Management not already our default, first-line institutional standard of care?’

I challenge healthcare decision-makers to evaluate the comprehensive scientific and economic evidence and identify a single defensible reason for delay.

The data demonstrate that none exists!”

Stay updated with Hemostasis Today.